Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07024173
PHASE3

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Sponsor: Shandong Suncadia Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.

Official title: A Multicenter, Open-label, Randomized Controlled Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer With Disease Progression After Previous Endocrine Therapy

Key Details

Gender

FEMALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2025-07-23

Completion Date

2027-12

Last Updated

2026-01-26

Healthy Volunteers

No

Interventions

DRUG

HRS-8080 Tablet

HRS-8080 tablet orally administered.

DRUG

Fulvestrant injection

Fulvestrant injection.

DRUG

Exemestane tablets

Exemestane tablets orally administered.

DRUG

Everolimus Tablets

Everolimus tablets orally administered.

DRUG

Anastrozole Tablets

Anastrozole tablets orally administered.

DRUG

Letrozole Tablets

Letrozole tablets orally administered.

Locations (2)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Hunan Cancer Hospital

Changsha, Hunan, China